USP20

Across TCGA pan-cancer cohorts, USP20 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated USP20 data layer compared with 27 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher USP20 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated USP20 expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

PDAC, GBM, and HNSC are the cancer types where USP20 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.243	0.596	.003	29	view →
GBM	DFS	Quartile	All	1.000	0.602	<.001	14	view →
HNSC	OS	Median	All	0.140	1.000	.017	13	view →
LUAD	DFS	Median	III,IV	0.765	0.386	.036	4	view →
CCRCC	DFS	Quartile	III,IV	0.528	1.000	.037	3	view →
LSCC	DFS	Median	II,III,IV	0.873	1.000	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

USP20–PDAC (OS)

Open the PDAC breakdown →